

**CURRICULUM VITAE**  
**Spencer David Dorn, MD, MPH, MHA**  
**Vice Chief, Division of Gastroenterology & Hepatology**  
**Associate Professor of Medicine, Health Policy & Management**  
**University of North Carolina**

Address: Division of Gastroenterology and Hepatology  
University of North Carolina School of Medicine  
CB 7080  
4153 Bioinformatics Building  
Chapel Hill, NC, 27599-7080  
919-966-0141 (phone)  
919-966-2250 (fax)  
[sdorn@med.unc.edu](mailto:sdorn@med.unc.edu)

**Education:**

|           |   |        |                            |
|-----------|---|--------|----------------------------|
| 1994-1998 | University of Michigan, Ann Arbor         | B.A.   | Political Science          |
| 1998-2002 | State University of New York, Brooklyn    | M.D.   | Medicine                   |
| 2005-2007 | University of North Carolina, Chapel Hill | M.P.H. | Epidemiology               |
| 2011-2013 | University of North Carolina, Chapel Hill | M.H.A. | Health Policy & Management |

**Post-Graduate Education:**

|           |  |
|-----------|--|
| 2002-2003 | Medicine Intern, Brigham and Women's Hospital, Harvard Medical School                |
| 2003-2005 | Medicine Resident, Brigham and Women's Hospital, Harvard Medical School              |
| 2005-2007 | Research Fellow in GI Epidemiology, University of North Carolina School of Medicine  |
| 2007-2009 | Clinical Fellow in Gastroenterology, University of North Carolina School of Medicine |

**Academic Positions:**

|           |   |
|-----------|---|
| 2009-2015 | Assistant Professor of Medicine, University of North Carolina School of Medicine                                |
| 2012-     | Director, UNC Gastroenterology Clinic   |
| 2013-     | Vice Chief for Clinical Operations, UNC Gastroenterology & Hepatology   |
| 2014-2016 | Adjunct Assistant Professor of Health Policy & Management, University of North Carolina School of Public Health |
| 2015-     | Associate Professor of Medicine, University of North Carolina School of Medicine                                |
| 2016-     | Adjunct Assistant Professor of Health Policy & Management, University of North Carolina School of Public Health |

**Medical Licensure**

|           |  |
|-----------|--|
| 2004-2005 | Commonwealth of Massachusetts # 221603 |
| 2005-     | State of North Carolina # 2005-01382   |

**Board Certification**

|           |   |
|-----------|---|
| 2005-2015 | Diplomat of the American Board of Internal Medicine                     |
| 2009-2019 | Diplomat of the American Board of Internal Medicine in Gastroenterology |

**Awards:**

- Michigan Annual Giving Merit Scholarship, 1994

- James B Angel Scholar, University of Michigan, 1997, 1998
- Phi Beta Kappa, University of Michigan, 1998
- Graduation with Highest Distinction, University of Michigan, 1998
- Alpha Omega Alpha Medical Honor Society, SUNY Brooklyn, 2001
- Merk Manual Award for Outstanding Students in Medical Studies, 2002
- Harold A. Lyons Award for Top Student in Clinical Medicine, SUNY Brooklyn, 2002
- Graduation Summa Cum Laude (Class Rank: 2/196), SUNY Brooklyn, 2002
- Graduation with Distinction in Research, College of Medicine, SUNY Brooklyn, 2002
- Excellence in Teaching, Tufts Medical School, 2005
- Gastroenterology Research Group Travel Award, 2009
- Delta Omega National Public Health Honor Society (Top 10% of Graduating Class), University of North Carolina, 2014
- Best Doctors in America®, 2015-2016
- American Gastroenterological Association Fellow, 2017

### **UNC Activities**

#### ***Undergraduate:***

- UNC Pre-health Advising Program, Guest Speaker, 2011-

#### ***School of Medicine:***

- UNC SOM Carolina Medical Student Research Program, Study Section, 2012-2013
- UNC SOM Internal Medicine Mentor Program, 2012-2014
- UNC SOM Strategic Plan (Quality Sub-section) Implementation Committee, 2012
- UNC SOM Carolina Value Information Technology Implementation Team, 2015
- UNC Department of Medicine Compensation Committee, 2015
- UNC Department of Medicine Clinical Program Directors Committee, 2015
- Carolina Digital Health Research Initiative, Advisory Board Member, 2016-

#### ***Health Care System:***

- UNC HCS Ambulatory Care Quality Workgroup, Member, 2010-2012
- UNC HCS Carolina Data Warehouse Operations Committee, 2010-
- UNC HCS Workflow, Data Usage, and Adoption Work Group, 2010
- UNC HCS Clinical Workstation Committee, 2010-2012
- UNC HCS Population Management Initiative Workgroup, 2011
- UNC HCS Department of Medicine Physician/Nurse Leadership Committee, 2012-
- UNC HCS Workgroup on Sensitive Clinical Information, 2012
- UNC HCS Lead Informatics Physician (EPIC Implementation) 2013-
- UNC HCS Physician Documentation Sub-Workgroup, Member, 2013
- UNC HCS EPIC Population Health Management Subgroup, Member, 2013-2014
- UNC HCS Referral Streamline Taskforce, 2013-2014
- UNC HCS Outpatient Care Services Executive Council, 2013-

- UNC HCS Institute for Healthcare Quality Improvement, Faculty, 2014-
- UNC HCS Carolina Value. Care Access Workgroup on Procedures and Staffing. 2015-2016
- UNC HCS Care Transformation Subcommittee-Expected Practices on GERD Management, 2016
- UNC Hospitals Patient Logistics Center Oversight Committee, 2017

### **Other Professional Activities**

- American Gastroenterological Association, Clinical Practice and Quality Management Committee, Member, 2011-2014
- American Gastroenterological Association, Quality Measures Committee, Member, 2014-2015
- American Gastroenterological Association Center for GI Innovation and Technology, Executive Management Board Member, 2011-2013
- American Gastroenterological Association Young GI Policy Committee, Member, 2012-2014
- American Gastroenterological Association, Think Tank for the Future of GI Practice. Advisor. 2011
- American Gastroenterology Association, Media Speaker's Bureau, 2013-
- American Gastroenterological Association, Public Affairs and Advocacy Regulatory Work Group, 2012-2014
- American Gastroenterological Association, Government Affairs Committee, 2014-
- American Gastroenterological Association, Physician Advisor Network. 2012 -
- American Gastroenterological Association, Practice Management and Economics Committee, 2015-
- American College of Gastroenterology National Scientific Meeting, Abstract Reviewer 2012.
- American Gastroenterological Association Constipation Medical Position Statement and Technical Summary Work Group, 2012
- Blue Cross Blue Shield of North Carolina, Physician Designation (Tiered Network) Program, Physician Advisory Board, 2011-2012
- Gastroenterology Multi-Society (AASLD, ACG, AGA, ASGE) Performance Measures Development Committee, 2013-2014
- EPIC Systems, "Gastroenterology Brain Trust," 2015-
- American Gastroenterological Association Digestive Diseases Week Abstract Reviewer, 2014-
- American Journal of Gastroenterology, Advisory Board, 2016-

### **Professional Societies**

- American College of Gastroenterology, 2009-
- American College of Physician Executives, 2011-
- American Gastroenterological Association, 2009-
- Beryl Institute for Patient Experience, 2012-
- Functional Brain Gut Group, 2007-
- Gastroenterology Research Group, 2005-2011
- North Carolina Gastroenterology Society, 2011-

### **Ad Hoc Reviewer (selected since 2005)**

- American Journal of Gastroenterology
- Alimentary Pharmacology and Therapeutics

- Annals of Internal Medicine
- Clinical Gastroenterology and Hepatology
- Digestive Diseases and Sciences
- Gastroenterology
- Gut
- Health Affairs
- Inflammatory Bowel Diseases
- Journal of Gastroenterology and Hepatology
- Nature Reviews in Gastroenterology and Hepatology

**Current Research Support – Federal Grants and Investigator-Initiated Studies:**

1. UNC Center for Health Innovation Pilot Award (Dorn, Klein PI). Optimizing Procedure Scheduling and Attendance Using Fast Healthcare Interoperability Resources (FHIR) and Natural Language Processing. 7/1/17-6/30/18. \$48,801.

**Completed Research Support – Federal Grants and Investigator-Initiated Studies:**

1. K12 HS19468-01 (Weinberger, PI). Comparative Effectiveness Research Mentored Career Development Award. Developing an Innovative and Feasible Model of Care for Irritable Bowel Syndrome. 7/2011-6/2013.
2. Ironwood Pharmaceuticals (Co-PI with Douglas Drossman). Patient-Reported Data Collection to Improve Care for Functional GI Disorders. 9/2009-6/2011, \$54,542.
3. Salix Pharmaceuticals (Co-PI with Douglas Drossman). Patient-Reported Data Collection to Improve Care for Functional GI Disorders. 1/2010-9/2011, \$50,000.
4. Takeda Pharmaceuticals (Co-PI with Douglas Drossman). Patient-Reported Data Collection to Improve Care for Functional GI Disorders, 1/2012-, \$146,300.
5. Forest Labs - (Co-PI with Douglas Drossman). Double blind randomized placebo control trial of Milnacipran in IBS, 1/2012-, \$390,390.80.
6. R01CA168959-01A1. (PI: Mehrotra). Measuring and Improving Colonoscopy Quality Using Natural Language Processing. 3/2013 – 3/2017. 1.0 calendar month.

**Current Research Support –Industry Sponsored Studies:**

1. An open-label, long-term safety study of oral linaclotide administered to adult patients with irritable bowel syndrome with constipation and/or chronic idiopathic constipation. LIN-MD-10. Actavis Pharmaceuticals, \$100,440.
2. Second Phase 3 Randomized, 12-Week, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation (IBS-C), Synergy Pharmaceuticals.

**Completed Research Support –Industry Sponsored Studies:**

1. An Open-Label, Long-Term Safety Study of Oral Linaclotide Administered to Patients with Chronic Constipation or Irritable Bowel Syndrome with Constipation. MCP 103-305. Ironwood, 10/01/2008-08/15/2011, \$51,400.

2. A Randomized, Double-blind, Placebo Controlled Study to Assess the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C). Ardelyx, 7/01/2011 – 6/30/2012, \$51,979.
3. A 12-Week, Randomized Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects with Diarrhea-Predominant Irritable Bowel Syndrome. ASMP3001. Tioga, 4/01/2011-2/28/2013, \$45,100.
4. A Randomized, 12-Week, Double-Blind, Placebo-Controlled, Repeat-Dose, Oral, Dose-Ranging Study to Assess the Safety and Efficacy of Plecanatide in Patients with Chronic Idiopathic Constipation. Synergy, 12/15/2011- 12/15/2012, \$56,194.
5. A Phase 2, Multi-Center, Randomized, Double Blind, Placebo-Controlled, Multiple-Dose Study to Determine the Safety and Efficacy of Orally Administered LX1033 in Subjects with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D). Lexicon, 02/15/2012-12/02/2012, \$66,086.
6. A Phase 3B, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial of Linaclotide Administered Orally for 12 Weeks to Patients with Chronic Constipation and Prominent Abdominal Bloating at Baseline. LIN-MD-04. Forest, 08/23/2012-08/22/2013, \$80,170.
7. A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome. 27018966IBS3002. Furiex, 05/19/2012-05/18/2014, \$67,986.56.
8. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Treatment Group, Multicenter Efficacy and Safety Study of Topical Diltiazem Hydrochloride 2% Cream in Subjects with Anal Fissure. VEN307-AF-001. Ventrus, 1/1/2013-5/1/2014. \$96,881.60.
9. A Multicenter, Randomized, Placebo-controlled, Double-blind Study of the Efficacy, Safety, and Pharmacokinetics of Lubiprostone in Pediatric Subjects Aged  $\geq 6$  Years to  $< 18$  Years with Functional Constipation. Sucampo, \$80,097.
10. A randomized, 12-week, double-blind, placebo-controlled study to assess the safety and efficacy of plecanatide (3.0 and 6.0 mg) in patients with chronic idiopathic constipation, Synergy pharmaceuticals, \$74,500.
11. A Phase 2 Multicenter, Randomized, Double-Blind Placebo-Controlled, Parallel Group Trial of Oral Linaclotide Administered for 8 Weeks in Adult Outpatients with Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Chronic Non-Cancer Pain. LIN-MD-40. Forest Pharmaceuticals, \$37,011.52.
12. The development and validation of a blood test to identify IBS:DEFINE (Diagnostic Evaluation of Functional GI and IBS Networks). Prometheus Therapeutics and Diagnostics. \$366,220 (role: Sub-I; PI: Ringel-Kulka). 7/2014-6/2016.
13. An open-label long-term safety and tolerability study of plecanatide in patients with chronic idiopathic constipation, Synergy pharmaceuticals, \$61000

### **Bibliography:**

#### **Peer Reviewed Papers:**

1. Mydlo JH, Chawla S, **Dorn S**, Volpe MA, Shah S, Imperato PJ. Renal cancer and pregnancy in two different female cohorts. Canadian Journal of Urology. 2002;9:1634-6.

2. **Dorn SD**, Abad JF, Panagopolous G, Korelitz BI. Clinical characteristics of familial vs. sporadic Crohn's disease using the Vienna Classification. *Inflammatory Bowel Diseases*. 2004;10:201-206.
3. **Dorn SD**, Sandler RS. Inflammatory bowel disease is not associated with increased cardiovascular mortality: results from a systematic review and meta-analysis. *American Journal of Gastroenterology*. 2007;102:662-667.
4. **Dorn SD**, Lembo AJ, Park J, Canenguez K, Nam BH, Woods KB, Conboy LA, Stason WB, Kaptchuk TJ. A meta-analysis of the placebo response in complementary and alternative medicine trials of irritable bowel syndrome. *Neurogastroenterology and Motility*. 2007;19:630-637.
5. **Dorn SD**, Palsson OS, Thiwan SIM, Kanazawa M, Clark WC, van Tilburg MAL, Drossman DA, Scarlett Y, Levy RL, Ringel Y, Crowell MD, Olden KW, Whitehead WE. Colonic Pain Sensitivity in Irritable Bowel Syndrome is the Result of an Increased Tendency to Report Pain rather than Increased Neurosensory Sensitivity. *Gut*. 2007;102:662-667.
6. **Dorn SD**, Matchar DB. Cost-effectiveness Analysis of Strategies for Diagnosing Celiac Disease. *Digestive Diseases and Sciences*. 2008;53:680-688.
7. **Dorn SD**, Morris CB, Hu Y, Toner BB, Diamant N, Whitehead WE, Bangdiwala SI, Drossman DA. Irritable Bowel Subtypes defined by Rome II and Rome III Criteria are Similar. *Journal of Clinical Gastroenterology*. 2009;43:214-220.
8. **Dorn SD**. Clostridium Difficile Colitis in a Health Care Worker: Case Report and Review of the Literature. *Digestive Diseases and Science*. 2009;53:178-180.
9. Grover M, **Dorn SD**, Weinland SR, Dalton CB, Gaynes BN, Drossman DA. Atypical Antipsychotic Quetiapine in the Management of Severe, Refractory Functional Gastrointestinal Disorders. *Digestive Diseases and Sciences*. 2009; 54:1284-91.
10. **Dorn SD**, Farley JF, Hansen RA, Shah ND, Sandler RS. The effect of direct to consumer advertisement and physician promotion of tegaserod (Zelnorm) on physician visits, diagnoses, and prescriptions for irritable bowel syndrome and chronic constipation. *Gastroenterology*. 2009;137:214-20.
11. **Dorn SD**. Health care reform in 2009: a primer for gastroenterologists. *Clinical Gastroenterology and Hepatology*. 2009;7:1168-1173.
12. **Dorn SD**. Mid-level providers in gastroenterology. *American Journal of Gastroenterology*. 2010;105:246-251.
13. **Dorn SD**, Hernandez L, Minaya MT, Morris CB, Hu Y, Leserman J, Lewis S, Bangdiwala SI, Green PHR, Drossman DA. Development and validation of the Celiac Disease Quality of Life Survey (CD-QOL). *Alimentary Pharmacology and Therapeutics*. 2010;31:666-75.
14. **Dorn SD**, Shah ND, Berg BP, Naessens JM. Effect of weekend hospital admissions on gastrointestinal hemorrhage outcomes. *Digestive Diseases and Sciences*. 2010;55:1658-1666.
15. **Dorn SD**. Systematic Review: Self-Management for Irritable Bowel Syndrome. *Alimentary Pharmacology and Therapeutics*. 2010; 32:513-321.
16. **Dorn SD**, Hernandez L, Minaya MT, Morris CB, Hu Y, Leserman J, Bangdiwala SI, Green PHR, Drossman DA. Psychosocial factors are more Important than Disease Activity in Determining Gastrointestinal Symptoms and Health Status in Celiac Disease. *Digestive Diseases and Sciences*. 2010; 55:3154-3163.

17. **Dorn SD.** Gastroenterology in a New Era of Accountability: Part 1 - An Overview of Performance Measurement. *Clinical Gastroenterology and Hepatology.* 2011;9:563-566.
18. Kappelman MD, **Dorn SD,** Allen JI. Quality of Care for Gastrointestinal Conditions: a primer for gastroenterologists. *American Journal of Gastroenterology.* 2011;106:1182-1187.
19. **Dorn SD.** Gastroenterology in a New Era of Accountability: Part 2 – Developing and Implementing Performance Measures. *Clinical Gastroenterology and Hepatology.* 2011;9:660-664.
20. **Dorn SD.** Gastroenterology in a New Era of Accountability: Part 3 – Accountable Care Organizations. *Clinical Gastroenterology and Hepatology.* 2011;9:750-753.
21. **Dorn SD,** Morris CB, Schneck SE, Hopper TM, Hu Y, Kulkarni R, Weinland SR, Norton WF, Norton NJ, Drossman DA. Development and Validation of the Irritable Bowel Syndrome Satisfaction with Care Scale. *Clinical Gastroenterology and Hepatology.* 2011;9:1065-1071.
22. **Dorn SD,** Meek PD, Shah ND. Increasing Frequency of Opioid Prescriptions for Chronic Abdominal Pain in U.S. Outpatient Clinics. *Clinical Gastroenterology and Hepatology.* 2011;9:1078-1085.
23. **Dorn SD.** Health Care Reform: 2012 Update. *Gastrointestinal Endoscopy Clinics of North America.* 2012;22:1-14.
24. **Dorn SD,** Wei D, Farley JF, Shah ND, Shaheen NJ, Sandler RS, Kappelman MD. Impact of the 2008-2009 Economic Recession on Screening Colonoscopy Utilization Among the Insured. *Clinical Gastroenterology and Hepatology.* 2012;10:278-284.
25. Sheen E, **Dorn SD,** Brill JV, Allen JI. The Supreme Court has Ruled: Health Care Reform and The Road Ahead for Gastroenterology. *Clinical Gastroenterology and Hepatology.* 2012;10:1062-5.
26. Zingone F, Iavarone A, Tortora R, Imperatore N, Pellegrini TR, **Dorn SD,** Ciacci C. The Italian Translation of the Celiac Disease-Specific Quality of Life Scale in Celiac Patients on Gluten-Free Diets. *Dig Liv Dis.* 2013;45:115-8..
27. Bharucha AE, **Dorn SD,** Lembo A, Pressman A. American Gastroenterological Association Medical Position Statement on Constipation. *Gastroenterol;*2013;144:211-7.
28. **Dorn SD.** Surviving the Remaining Days of Fee-for-Service Payments. *Clinical Gastroenterology and Hepatology.* 2013;11:1212-1215..
29. **Dorn S,** Cremonini F, Lembo AJ. Opioid-Induced Bowel Dysfunction: Epidemiology, Pathophysiology, Diagnosis, and Initial Therapeutic Approach. *Amer J Gastroenterol.* 2014;10:31-37.
30. **Dorn SD,** Palsson OS, Woldegebriel M, Fowler B, McCoy R, Weinberger M, Drossman DA. Development and pilot testing of an integrated, web-based self-management program for irritable bowel syndrome (IBS). *Neurogastroenterol Motil.* 2015;27:128-134.
31. **Dorn SD.** Digital Health: Hope, Hype, and Reality. *Gastroenterology.* 2015;149:516-520.
32. **Dorn SD.** Quality Measurement in Gastroenterology: Confessions of a Realist. *Clinical Gastroenterology and Hepatology.* 2016;14:648-650.
33. **Dorn SD.** The Road Ahead 3.0: Changing Payments, Changing Practice. *Clinical Gastroenterology and Hepatology.* 2016. 14:785-789.
34. **Dorn SD,** Vesly CJ. Medicare’s Revaluation of Gastrointestinal Endoscopic Procedures: Implications for Academic and Community-Based Practices. *Clinical Gastroenterology and Hepatology.* 2016. 14:924-928.

### **Editorials and Letters:**

1. **Dorn SD.** Predictors of Crohn's disease. *Gastroenterology*. 2006;131:334-335.
2. **Dorn SD,** Ringel Y. Lubiprostone: Easing the strain of constipation? *Gastroenterology*. 2008;134 255-257.
3. **Dorn SD.** Medical economies. Response to letter from Kisloff, B. *Clinical Gastroenterology and Hepatology*. 2010;8:474.
4. **Dorn SD.** Commentary on: Linaclotide improved chronic constipation in two phase III trials. *Gastroenterology and Hepatology News*. November, 2010.
5. Palmer LB, **Dorn SD.** Increased mortality and length of stay among patients with inflammatory bowel disease and hospital-acquired infections. Effect of risk adjustment. *Clinical Gastroenterology and Hepatology*. 2011;9:446.
6. Allen JI, **Dorn SD,** Kappelman MD. Response to letter from Rowe IA, Parker R, and Houlihan DD. Appropriateness of hepatitis A vaccination in patients with hepatitis C. *American Journal of Gastroenterology*. 2012;107:485-486.
7. **Dorn, SD.** Recall systems for surveillance colonoscopy: Good safe patient care or unnecessary and potentially hazardous? *AGA Perspectives*. 2012; February/March:9.
8. **Dorn SD.** Accountable care organizations. Response to letter from Kisloff, B. *Clinical Gastroenterology and Hepatology*. 2012;10:442.
9. **Dorn SD,** Fendrick AM. Waiving cost sharing for colonoscopy – free, but not clear. *Clinical Gastroenterology and Hepatology*. 2012;10:767-8.

### **Non-peer reviewed articles:**

1. Drossman DA, **Dorn SD.** Evaluation and management of chronic diarrhea: An Algorithmic Approach. *Medscape Gastroenterology*, Medscape, Inc. 2005.  
<http://www.medscape.com/viewarticle/513578>
2. **Dorn SD.** Gastroenterology in a New Era of Accountability. Part I. *GI and Hepatology News*. 2012;6(3):22.
3. **Dorn SD.** Gastroenterology in a New Era of Accountability. Part II. *GI and Hepatology News*. 2012;6(4):22.
4. **Dorn SD.** Gastroenterology in a New Era of Accountability. Part III. *GI and Hepatology News*. 2012;6(6):22-23.
5. **Dorn SD.** Chronic constipation: differentiating IBS-C and CIC. *Medscape*, Inc. 2014  
<http://www.medscape.org/viewarticle/826706>
6. **Dorn SD.** Effective management of chronic symptoms of IBS-D. *Medcape*, Inc. 2015.  
<http://www.medscape.org/viewarticle/852554>

### **Book Chapters:**

1. Long M, **Dorn SD.** Irritable Bowel Syndrome. In: *Pregnancy, GI and Liver Disease: A practical approach* Editors: Isaacs KL, Long MD. Slack Publishing, 2012.

### **Book reviews:**



1. **Dorn SD**, Drossman DA. Review of Lacy B: Making Sense of IBS: A Physician Answers Your Questions about Irritable Bowel Syndrome. Johns Hopkins University Press, 2006. *Gastroenterology*. 2007;132:2615-2616.

**Published Abstracts:**

1. **Dorn SD**, Lembo AJ, Park J, Canenguez K, Nam BH, Woods KB, Conboy LA, Stason WB, Kaptchuk TJ. A meta-analysis of the placebo response in complementary and alternative medicine trials of irritable bowel syndrome. *Neurogastroenterology and Motility 2006 Joint International Meeting*. September 14-17, 2006. Boston.
2. **Dorn, SD**, Palsson OS, Thiwan SIM, Kanazawa M, Clark WC, van Tilburg MAL, Drossman DA, Scarlett Y, Levy RL, Ringel Y, Crowell MD, Olden KW, Whitehead, WE. Increased Colonic Sensitivity in Irritable Bowel Syndrome is the Result of Increased Perceptual Response Bias rather than Increased Perceptual Sensitivity. *Gastroenterology*. 2006;130:A443
3. **Dorn SD**, Morris CB, Hu Y, Toner BB, Diamant N, Whitehead WE, Bangdiwala SI, Drossman DA. Lack of Agreement for Irritable Bowel Syndrome Subtypes for Rome III between Retrospective Questionnaire and Prospective Diary Cards. *Gastroenterology*. 2007;132:A681
4. Weinland SR, **Dorn SD**, Morris CB, Hu Y, Dalton CB, Toner BB, Diamant N, Whitehead WE, Bangdiwala SI, Drossman DA. Antecedent Event-Specific Associations for Diarrhea and Constipation with Functional Bowel Disorder. *Gastroenterology*. 2007;132:A677
5. Whitehead WE, Palsson OS, Kanazawa M, Ganagarosa L, Thiwan SI, Drossman D, Van Tilburg A, Chitkara D, **Dorn S**, Ringel Y, Turner M. Cluster Analysis Evidence that Irritable Bowel Syndrome is not a Single Disorder but a Collection of Distinct Syndromes. *Gastroenterology*, 2007;132:A148
6. Palsson OS, Kanazawa M, Van Tilburg MA, Thiwan S, Ringel Y, **Dorn SD**, Gangarosa LM, Turner M, Drossman DA, Whitehead WE. Determinants of Irritable Bowel Syndrome Severity. *Gastroenterology*, 2007;132:A677
7. Grover M, **Dorn SD**, Weinland SR, Dalton CB, Gaynes BN, Drossman DA. Atypical Antipsychotic Quetiapine in the Management of Severe, Refractory Functional Gastrointestinal Disorders. *American Journal of Gastroenterology*. 2008;103:A1181
8. **Dorn SD**, Hernandez L, Minaya MT, Morris CB, Hu Y, Leserman J, Bangdiwala SI, Green PHR, Drossman DA. Psychosocial factors are more Important than Disease Activity in Determining Gastrointestinal Symptoms and Health Status in Celiac Disease. *Gastroenterology*. 2009;136:A29
9. **Dorn SD**, Farley JF, Hansen RA, Shah ND, Sandler RS. The effect of direct to consumer advertisement and physician promotion of tegaserod (Zelnorm) on physician visits, diagnoses, and prescriptions for irritable bowel syndrome and chronic constipation. *Gastroenterology*. 2009;136:A36
10. **Dorn SD**, Morris CB, Hu YJ, Norton NJ, Norton WF, Bangdiwala SI, Drossman DA. Patients with IBS commonly use narcotics. *Gastroenterology*. 2010; W1378
11. **Dorn SD**, Morris CB, Hu YJ, Norton NJ, Norton WF, Bangdiwala SI, Drossman DA. Predictors of satisfaction with care among patients with irritable bowel syndrome. *Gastroenterology* 2010; W1379

12. Crocker J, **Dorn SD**, Morris C, Hu J, Drossman D. Inpatient consultations of patients with functional GI disorders at a tertiary care center: the value of diagnostic testing. *Am J Gastroenterology*. 2010;105:1313
13. **Dorn SD**, Morris CB, Schneck SE, Hopper TM, Hu JB, Kulkarni R, Weinland SR, Norton WF, Norton NJ, Drossman DA. Development and Validation of the Irritable Bowel Syndrome Satisfaction with Care Scale (IBS-SAT). *Gastroenterology*. 2011;140:S615.
14. **Dorn SD**, Meek PD, Shah ND. U.S. Patients with Chronic Abdominal Pain are Increasingly Prescribed Opioid Analgesics. *Gastroenterology*. 2011;140:S206.
15. **Dorn SD**, Wei D, Farley JF, Shah ND, Shaheen NJ, Sandler RS, Kappelman MD. Impact of the 2008-2009 Economic Recession on Colonoscopy Utilization Among the Insured. *Gastroenterology*. 2011;140:S51.
16. Rybnicek DA, **Dorn SD**, Shaheen NJ, Dellon ES. Can an internet search tool provide clues into the evolving epidemiology of eosinophilic esophagitis? *Gastroenterology*. 2012; 2012;142:S-436.
17. **Dorn SD**, Meek PD. Ambulatory care for irritable bowel syndrome in the United States, 1993-2010. *Gastroenterology*. 2013;144:S-378.
18. Leffler DA, Schoen RE, Strotmeyer S, Germansky KA, Dean K, Carrell D, Dellon E, Crockett SD, **Dorn S**, Mehrotra A. Endoscopist. Perspectives on Colonoscopy Quality and Surveillance Guidelines: Results of a Multicenter United States Survey. *Gastroenterology*. 2016; 2016;150:S-644.
19. Leffler DA, Schoen RE, Strotmeyer S, Germansky KA, Dean K, Carrell D, Dellon E, Crockett SD, **Dorn S**, Mehrotra A. Endoscopist. Engaging Gastroenterologists in Qualitative Research: Novel Methods for Enhancing Response Rates. *Gastroenterology*. 2016;150:S-645.
20. Lubarda J, Chatterjee P, Muino J, **Dorn, SD**. Can Continuing Education Improve Effective Management of IBS-D? *Gastroenterology*. 2017. *In press*.
21. Fogel R, Dorn S, Krause R, Eng P, Kirshoff MS, Nguyen A, Griffin P. Efficacy and Safety of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation: Results from 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trials. *Gastroenterology*. 2017. *In press*.

#### **National Presentations and Panels:**

1. "Psychosocial factors are more Important than Disease Activity in Determining Gastrointestinal Symptoms and Health Status in Celiac Disease." *Digestive Diseases Week*. Chicago, IL. 2009.
2. "The effect of direct to consumer advertisement and physician promotion of tegaserod (Zelnorm) on physician visits, diagnoses, and prescriptions for irritable bowel syndrome and chronic constipation." *Digestive Diseases Week*. Chicago, IL. 2009.
3. "Impact of the 2008-2009 Economic Recession on Colonoscopy Utilization Among the Insured." *Digestive Diseases Week*, Chicago, IL. 2011.
4. "Accountable Care Organizations and What it Means for the Practice of Gastroenterology for the Gastroenterologist." (Session Moderator). *Digestive Diseases Week*, Chicago, IL. 2011.
5. "Maximizing Cost-Effectiveness in GI Health Care." (Session Moderator). *Digestive Diseases Week*, San Diego, CA. 2012.

6. "Shifting Reimbursement, Bundled Payments and the Link to Evidence Based Medicine." Digestive Diseases Week, Orlando, FL. 2013.
7. "Implications of Health Care Reform on Endoscopy Practice." Digestive Diseases Week, Orlando, FL. 2013.
8. "Optimizing the Diagnosis, Treatment, and Management of Irritable Bowel Syndrome." Pri-Med CME Updates, Baltimore, St. Louis and Houston. 2014-2015
9. "Quality Measurement in Gastroenterology. How Did We Get Here? Where Are We Going?" Digestive Diseases Week, Washington, DC. 2015.
10. "Current Concepts in Provider and System-Based Quality of Care Measurement." Digestive Diseases Week, Washington, DC. 2015.
11. "Digital Health and Social Media for the Gastroenterologist." Post Graduate Course. Digestive Diseases Week, San Diego, CA. 2016.
12. Finding Solid Ground in a Shifting IBD Healthcare Landscape. University of Kentucky, Division of Gastroenterology. June 14, 2016.
13. Recognition of Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D): Advancing Accurate Diagnosis and Treatment. Mississippi Association of Family Practice Annual Scientific Assembly. Destin, FL. 2016.
14. Recognition of Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D): Advancing Accurate Diagnosis and Treatment. Georgia Academy of Family Physicians Annual Meeting. Atlanta, Georgia. 2016
15. Measuring Value in Academic Gastroenterology: Opportunities and Challenges. GI Division Chief's Meeting. Digestive Diseases Week, Chicago, IL. 2017.
16. Effect of the 2017 Elections on Gastroenterology. Digestive Diseases Week, Chicago, IL. 2017.
17. Gastroenterology in the Era of Trump. (Panel Discussion). Digestive Diseases Week, Chicago, IL. 2017.

*Revised May 6, 2017*